Declining ALS Patients Are Waiting On The FDA...

Diesel prices are hitting new highs, and voters aren’t happy. With the midterms approaching, the Trump administration is trying to find ways to curb fuel costs, including a potential US diesel export ban. On today’s Big Take podcast: The political fallout of sky-high diesel price ...  Show more

As Chinese President Xi Jinping makes his first visit to Washington in over a decade, trade and the AI race will likely dominate talks with Donald Trump. On today’s Big Take Asia podcast, host K. Oanh Ha and Bloomberg’s John Liu unpack what each leader hopes to gain and why they ...  Show more

ALS is a fatal neurological disease that kills motor neurons. Even though it was first described more than 150 years ago, there is no cure, and the few drugs available only dampen the symptoms or slow the progression by a few months. In recent years new drugs have emerged. How ...

ALS is a disease that destroys the nerve cells in the brain and spinal cord we need for voluntary movement. There is no cure, but now there is a newly approved medication that may slow down the disease and extend patients' lives. The drug, called Relyvrio, got its start with a co ...  Show more

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more